Iovance Biotherapeutics Inc

Latest Results (03.11.2026):

Iovance Biotherapeutics Inc — Second Quarter 2026: Iovance reported record Q2 2026 product revenue of $99.3 million (up 66% year‑over‑year), driven principally by U.S. Amtagvi sales (~$91M). Gross margin expanded to 56% and the company narrowed its GAAP net loss to $47.3 million ($0.11 per share) versus $111.7 million in Q2 2025. Cash and investments were about $304 million at June 30, 2026, with management reviewing FY2026 revenue guidance ($350–$370M) and planning an update in Q3.

Top-line revenue

Q2 product revenue: $99.3M (vs $60.0M in Q2 2025). U.S. Amtagvi revenue was ~$91M; Global Proleukin revenue ≈ $9M and is expected to grow through 2026.

Profitability and margins

Gross margin improved to 56% (ex‑D&A), attributed to higher Amtagvi volumes, cost optimization, and maturing internal manufacturing. Cost of sales for the quarter was $43.6M.

Earnings and operating results

GAAP net loss for Q2 2026: $47.3M ($0.11 per share) compared with a net loss of $111.7M ($0.33) in Q2 2025. Total costs and expenses fell to $151.2M from $173.7M a year earlier; R&D expense showed further sequential improvement (R&D down ~6% vs Q1 2026).

Balance sheet and cash runway

Cash, cash equivalents and investments totaled about $304M (including restricted cash) as of June 30, 2026. Management expects current cash to fund operations into the second half of 2028.

Guidance update

Management is reviewing full‑year 2026 revenue guidance of $350–$370M in light of strong Q2 performance and will provide an updated outlook in Q3 2026.

Commercial progress — Amtagvi

Commercial momentum: record demand supported by a larger sales force and marketing; unaided physician awareness nearly tripled year‑over‑year. Authorized treatment center (ATC) network exceeds 95 centers (targeting ≥110 by year‑end). Manufacturing turnaround time is 31 days or less.

Regulatory and clinical pipeline

Regulatory/clinical highlights: FDA Fast Track Designation for lifileucel in soft tissue sarcomas (UPS/DDLPS) and supportive FTD actions in non‑squamous NSCLC; SARATOGA registrational trial underway with early ORR ~50% in initial patients; IOV‑LUN‑202 enrollment nearly complete with updates expected in 4Q26 and an sBLA planned for 2027; TILVANCE‑301 Phase 3 is enrolling; multiple next‑generation programs (IOV‑4001, IOV‑5001, IOV‑3001) and IST activity ongoing.

Other corporate notes

Company highlights a broad IP portfolio (400+ granted/allowed patents and >1,000 applications) with potential exclusivity into at least 2042, deployment of AI initiatives for efficiencies, and continued international regulatory activity (Australia approval in hand; UK resubmission under expedited review; Switzerland expected 1H27; EMA resubmission planned for 2027).